Stay updated with breaking news from Smartcells Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd.
/PRNewswire/ -- According to Coherent Market Insights, the global stem cell banking market is estimated to be valued at US$ 4,483.31 million in 2022 and is...
Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
Press release content from Business Wire. The AP news staff was not involved in its creation.
Up to 600 volunteers will participate in an AKS-452 COVID booster study in the Netherlands to investigate boosting the immune response of those previously vaccinated with EMA-registered vaccines